INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Option exerciseVerified data

Szwarcberg Javier B. reported SPRB

Director, CHIEF EXECUTIVE OFFICER · SPRUCE BIOSCIENCES, INC. · Common Stock

Side
M
Value
—
Shares
4,950
Price
—
Executed
Dec 11, 2025
Disclosed
Dec 12, 2025
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Dec 11 executedDec 12, 2025 disclosed

SPRB · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 48.3% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SPRB

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    15
    BP
    Barretto-Ko PercivalDirector
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    1,700 sh
    		May 21, 2026May 26, 2026
    traded May 21, 2026
    		+5dSEC FORM 4

    Evidence

    15
    WK
    Walbert KeliDirector
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    1,700 sh
    		May 21, 2026May 26, 2026
    traded May 21, 2026
    		+5dSEC FORM 4

    Evidence

    19
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    5,000 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    31
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Option exercise
    		M—
    1,250 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    19
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    266 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    19
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Disposition to issuer
    		D—
    266 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    19
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Disposition to issuer
    		D—
    400 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    19
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    400 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    19
    WK
    Ways Douglas KirkDirector, Interim Chief Medical Officer
    SPRBSPRUCE BIOSCIENCES, INC.
    Option exercise
    		M—
    1,250 sh
    		Dec 11, 2025Jan 21, 2026
    traded Dec 11, 2025
    		+41dSEC FORM 4

    Evidence

    9
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Option exercise
    		M—
    1,480 sh
    		Dec 15, 2025Dec 17, 2025
    traded Dec 15, 2025
    		+2dSEC FORM 4

    Evidence

    13
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Option exercise
    		M—
    1,480 sh
    		Dec 15, 2025Dec 17, 2025
    traded Dec 15, 2025
    		+2dSEC FORM 4

    Evidence

    16
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Tax withholding
    		F$61K
    752 sh
    		Dec 15, 2025Dec 17, 2025
    traded Dec 15, 2025
    		+2dSEC FORM 4

    Evidence

    13
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Option exercise
    		M—
    1,196 sh
    		Dec 15, 2025Dec 17, 2025
    traded Dec 15, 2025
    		+2dSEC FORM 4

    Evidence

    9
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Tax withholding
    		F$49K
    608 sh
    		Dec 15, 2025Dec 17, 2025
    traded Dec 15, 2025
    		+2dSEC FORM 4

    Evidence

    15
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    1,666 sh
    		Dec 11, 2025Dec 17, 2025
    traded Dec 11, 2025
    		+6dSEC FORM 4

    Evidence

    15
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Disposition to issuer
    		D—
    1,666 sh
    		Dec 11, 2025Dec 17, 2025
    traded Dec 11, 2025
    		+6dSEC FORM 4

    Evidence

    21
    SB
    Szwarcberg Javier B.Director, CHIEF EXECUTIVE OFFICER
    SPRBSPRUCE BIOSCIENCES, INC.
    Option exercise
    		M—
    1,196 sh
    		Dec 15, 2025Dec 17, 2025
    traded Dec 15, 2025
    		+2dSEC FORM 4

    Evidence

    9
    BP
    Barretto-Ko PercivalDirector
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    800 sh
    		Dec 11, 2025Dec 15, 2025
    traded Dec 11, 2025
    		+4dSEC FORM 4

    Evidence

    9
    WK
    Walbert KeliDirector
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    3,400 sh
    		Dec 11, 2025Dec 15, 2025
    traded Dec 11, 2025
    		+4dSEC FORM 4

    Evidence

    9
    SV
    Simpson Camilla VDirector
    SPRBSPRUCE BIOSCIENCES, INC.
    Grant or award
    		A—
    362 sh
    		Dec 11, 2025Dec 15, 2025
    traded Dec 11, 2025
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001903669-25-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 11, 2025
    Published
    Dec 12, 2025
    Ingested by INSIDER
    Nov 5, 04:28 UTC
    Last re-read
    Nov 5, 04:28 UTC

    Extracted facts

    Filer
    Szwarcberg Javier B.
    Role
    Director, CHIEF EXECUTIVE OFFICER
    Transaction
    Option exerciseAs filed: “M”
    Asset
    SPRUCE BIOSCIENCES, INC.
    Ticker
    SPRB
    Shares
    4,950
    Price per share
    $0
    Execution date (reported)
    Dec 11, 2025
    Owned after transaction
    15.2K shares
    Days from execution to publication
    1

    What this establishes

    Szwarcberg Javier B. filed this Form 4 reporting a option exercise of SPRB on Dec 11, 2025. It became public on Dec 12, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CHIEF EXECUTIVE OFFICER
    Szwarcberg Javier B.cik:0001903669
    Issuer
    SPRUCE BIOSCIENCES, INC.cik:0001683553

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.